drugset / Trial / NCT02721979
Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance
Phase 2
Terminated
24 enrolled
University of Washington
Janssen Scientific Affairs, LLC · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well apalutamide works in treating patients with prostate cancer who are in active surveillance. Testosterone can cause the growth of prostate cancer cells. Hormone therapy using androgen receptor antagonist apalutamide may fight prostate cancer by blocking the use of testosterone by the tumor cells.
Timeline
- Start
- 2017-11-02
- Primary completion
- 2020-02-12
- Completion
- 2021-11-30
Outcome
Outcome not reported
Stopped (Enrollment): “Terminated due to slow accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apalutamide | Small molecule | — | Oral |